# COMT on Aspirin Platelets Effects (CAPE)

> **NCT03433586** · PHASE4 · UNKNOWN · sponsor: **Brigham and Women's Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** Aspirin 81 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03433586
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-10
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2021-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03433586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03433586, "COMT on Aspirin Platelets Effects (CAPE)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03433586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*